Startseite › Multiples Myelom › Ohio › Cincinnati
Klinische Studien zu Multiples Myelom in Cincinnati, OH
17 Studien zu Multiples Myelom suchen Teilnehmer an Standorten in und um Cincinnati (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Teilnehmer gesuchtPhase 3
- Research Site, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- The Christ Hospital, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Teilnehmer gesuchtPhase 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 mi entfernt
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Teilnehmer gesuchtPhase 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Teilnehmer gesuchtPhase 3
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Teilnehmer gesuchtPhase 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- und 4 weitere
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Teilnehmer gesuchtPhase 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- und 1 weitere
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Teilnehmer gesuchtPhase 3
- Research Site, Cincinnati
- Research Site, Montgomery · 11 mi entfernt
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Teilnehmer gesuchtPhase 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Teilnehmer gesuchtPhase 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- und 2 weitere
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Teilnehmer gesuchtPhase 3
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Teilnehmer gesuchtPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Oncology Hematology Care, Inc, Cincinnati
Multiples Myelom-Studien in anderen Städten
- New York City, NY60 Studien
- Boston, MA42 Studien
- Atlanta, GA41 Studien
- Houston, TX38 Studien
- Durham, NC37 Studien
- Nashville, TN32 Studien
- Denver, CO27 Studien
- Columbus, OH24 Studien
- Rochester, MN24 Studien
- St. Louis, MO24 Studien
- Baldwin Park, CA23 Studien
- Chicago, IL22 Studien
Weitere Studien in Cincinnati
- Nichtkleinzelliges Lungenkarzinom35 Studien
- Krebs (alle Arten)27 Studien
- Brustkrebs25 Studien
- Herzinsuffizienz24 Studien
- Kolorektales Karzinom21 Studien
- Metastasierender Krebs20 Studien
- Akute myeloische Leukämie20 Studien
- Lungenkrebs19 Studien
- Eierstockkrebs19 Studien
- Adipositas19 Studien
- Prostatakrebs18 Studien
- Melanom17 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 02.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.